Disala Fernando

595 total citations
17 papers, 373 citations indexed

About

Disala Fernando is a scholar working on Rheumatology, Radiology, Nuclear Medicine and Imaging and Physiology. According to data from OpenAlex, Disala Fernando has authored 17 papers receiving a total of 373 indexed citations (citations by other indexed papers that have themselves been cited), including 4 papers in Rheumatology, 3 papers in Radiology, Nuclear Medicine and Imaging and 3 papers in Physiology. Recurrent topics in Disala Fernando's work include Pain Management and Opioid Use (2 papers), Pain Mechanisms and Treatments (2 papers) and Chronic Lymphocytic Leukemia Research (2 papers). Disala Fernando is often cited by papers focused on Pain Management and Opioid Use (2 papers), Pain Mechanisms and Treatments (2 papers) and Chronic Lymphocytic Leukemia Research (2 papers). Disala Fernando collaborates with scholars based in United Kingdom, United States and Australia. Disala Fernando's co-authors include Dennis L. Sprecher, N. Wesley Norton, Peter J. Skrdla, Joseph Cheriyan, Navin Goyal, Gil Yosipovitch, Stewart W. McCallum, Rachel A. Gibson, Stefano Zamuner and Chiara Zecchin and has published in prestigious journals such as PLoS ONE, Pain and Journal of Pharmacology and Experimental Therapeutics.

In The Last Decade

Disala Fernando

16 papers receiving 364 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Disala Fernando United Kingdom 11 101 84 72 70 54 17 373
Victoria Lyo United States 10 79 0.8× 105 1.3× 122 1.7× 42 0.6× 63 1.2× 33 635
Sanela Tarabar United States 11 23 0.2× 88 1.0× 76 1.1× 77 1.1× 89 1.6× 14 452
Se-Jin Kim South Korea 9 26 0.3× 76 0.9× 56 0.8× 99 1.4× 21 0.4× 14 303
Simone Vanoni United States 11 37 0.4× 88 1.0× 84 1.2× 80 1.1× 13 0.2× 17 300
Marion Brollo France 12 103 1.0× 83 1.0× 112 1.6× 108 1.5× 7 0.1× 23 464
Norio Kihara Japan 7 64 0.6× 197 2.3× 111 1.5× 86 1.2× 10 0.2× 15 456
Rebecca J. Steagall United States 11 30 0.3× 89 1.1× 125 1.7× 27 0.4× 97 1.8× 15 516
Charlotte Abrial France 8 102 1.0× 69 0.8× 88 1.2× 76 1.1× 5 0.1× 12 377
C. Winkler Germany 8 15 0.1× 106 1.3× 66 0.9× 58 0.8× 15 0.3× 23 334
Jieli Wu China 10 20 0.2× 22 0.3× 117 1.6× 59 0.8× 31 0.6× 25 358

Countries citing papers authored by Disala Fernando

Since Specialization
Citations

This map shows the geographic impact of Disala Fernando's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Disala Fernando with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Disala Fernando more than expected).

Fields of papers citing papers by Disala Fernando

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Disala Fernando. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Disala Fernando. The network helps show where Disala Fernando may publish in the future.

Co-authorship network of co-authors of Disala Fernando

This figure shows the co-authorship network connecting the top 25 collaborators of Disala Fernando. A scholar is included among the top collaborators of Disala Fernando based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Disala Fernando. Disala Fernando is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Begg, Malcolm, Augustin Amour, Teresa Tang, et al.. (2023). An open label trial of nemiralisib, an inhaled PI3 kinase delta inhibitor for the treatment of Activated PI3 kinase Delta Syndrome. Pulmonary Pharmacology & Therapeutics. 79. 102201–102201. 13 indexed citations
2.
Begg, Malcolm, Augustin Amour, Emily Jarvis, et al.. (2022). An Open Label Trial of Nemiralisib, an Inhaled PI3 Kinase Delta Inhibitor for the Treatment of Activated PI3 Kinase Delta Syndrome. SSRN Electronic Journal. 3 indexed citations
3.
Cheriyan, Joseph, Alexandra H. Roberts, Caleb Roberts, et al.. (2022). Evaluation of Dynamic Contrast‐Enhanced MRI Measures of Lung Congestion and Endothelial Permeability in Heart Failure: A Prospective Method Validation Study. Journal of Magnetic Resonance Imaging. 56(2). 450–461.
4.
Brown, Jack A., Monica Simeoni, Peter Williams, et al.. (2021). A randomized study of the safety and pharmacokinetics of GSK3358699, a mononuclear myeloid‐targeted bromodomain and extra‐terminal domain inhibitor. British Journal of Clinical Pharmacology. 88(5). 2140–2155. 5 indexed citations
5.
Fernando, Disala, Sara Soleman, Sarah K. Walsh, et al.. (2021). Assessment of the safety, pharmacokinetics and pharmacodynamics of GSK3335065, an inhibitor of kynurenine monooxygenase, in a randomised placebo‐controlled first‐in‐human study in healthy volunteers. British Journal of Clinical Pharmacology. 88(2). 865–870. 4 indexed citations
6.
Joshi, Samit R., Disala Fernando, Thomas Greene, et al.. (2020). Phase I evaluation of the safety, tolerability, and pharmacokinetics of GSK3640254, a next‐generation HIV‐1 maturation inhibitor. Pharmacology Research & Perspectives. 8(6). e00671–e00671. 22 indexed citations
7.
Begg, Malcolm, J. Hamblin, Robert C. Wilson, et al.. (2019). Translation of Inhaled Drug Optimization Strategies into Clinical Pharmacokinetics and Pharmacodynamics Using GSK2292767A, a Novel Inhaled Phosphoinositide 3-Kinase δ Inhibitor. Journal of Pharmacology and Experimental Therapeutics. 369(3). 443–453. 14 indexed citations
8.
Goyal, Navin, Peter J. Skrdla, Disala Fernando, et al.. (2019). Clinical Pharmacokinetics, Safety, and Tolerability of a Novel, First-in-Class TRPV4 Ion Channel Inhibitor, GSK2798745, in Healthy and Heart Failure Subjects. American Journal of Cardiovascular Drugs. 19(3). 335–342. 106 indexed citations
9.
Groot, Marius de, Neel Patel, Roido Manavaki, et al.. (2019). Quantifying disease activity in rheumatoid arthritis with the TSPO PET ligand 18F-GE-180 and comparison with 18F-FDG and DCE-MRI. EJNMMI Research. 9(1). 113–113. 10 indexed citations
10.
Richards, Duncan, Mark J. Bamford, Lia Liefaard, et al.. (2019). Identification, preclinical profile, and clinical proof of concept of an orally bioavailable pro‐drug of miridesap. British Journal of Pharmacology. 177(8). 1853–1864. 3 indexed citations
11.
Reid, Juliet, Stefano Zamuner, Maria Feeney, et al.. (2018). In vivo affinity and target engagement in skin and blood in a first‐time‐in‐human study of an anti‐oncostatin M monoclonal antibody. British Journal of Clinical Pharmacology. 84(10). 2280–2291. 33 indexed citations
12.
Fernando, Disala, Sarah Siederer, Ian Schneider, et al.. (2017). Safety, Tolerability and Pharmacokinetics of Single Doses of Oxytocin Administered via an Inhaled Route in Healthy Females: Randomized, Single-blind, Phase 1 Study. EBioMedicine. 22. 249–255. 20 indexed citations
13.
Bouma, Gerben, Stefano Zamuner, Andrew Want, et al.. (2017). CCL20 neutralization by a monoclonal antibody in healthy subjects selectively inhibits recruitment of CCR6+ cells in an experimental suction blister. British Journal of Clinical Pharmacology. 83(9). 1976–1990. 34 indexed citations
14.
Ziauddeen, Hisham, Liam J. Nestor, Naresh Subramaniam, et al.. (2016). Opioid Antagonists and the A118G Polymorphism in the μ-Opioid Receptor Gene: Effects of GSK1521498 and Naltrexone in Healthy Drinkers Stratified by OPRM1 Genotype. Neuropsychopharmacology. 41(11). 2647–2657. 15 indexed citations
15.
16.
17.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Victoria Lyo Breakdown of academic impact, for papers by Sanela Tarabar Breakdown of academic impact, for papers by Se-Jin Kim Breakdown of academic impact, for papers by Simone Vanoni Breakdown of academic impact, for papers by Marion Brollo Breakdown of academic impact, for papers by Norio Kihara Breakdown of academic impact, for papers by Rebecca J. Steagall Breakdown of academic impact, for papers by Charlotte Abrial Breakdown of academic impact, for papers by C. Winkler Breakdown of academic impact, for papers by Jieli Wu
Rankless by CCL
2026